ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $105.00 Average PT from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $105.00.

Several research analysts have commented on the company. Guggenheim reaffirmed a “buy” rating and set a $124.00 target price on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Canaccord Genuity Group began coverage on ANI Pharmaceuticals in a research note on Thursday, July 16th. They issued a “hold” rating and a $91.00 price target for the company. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd.

Insider Activity

In other news, CEO Nikhil Lalwani sold 55,000 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the sale, the chief executive officer directly owned 349,889 shares in the company, valued at $27,140,889.73. This represents a 13.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director directly owned 38,432 shares of the company’s stock, valued at $3,098,772.16. This represents a 20.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 85,179 shares of company stock worth $6,722,596. 8.10% of the stock is owned by insiders.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. grew its holdings in ANI Pharmaceuticals by 6.9% during the 1st quarter. Pacer Advisors Inc. now owns 85,467 shares of the specialty pharmaceutical company’s stock worth $6,572,000 after acquiring an additional 5,548 shares during the period. Bank of America Corp DE lifted its stake in shares of ANI Pharmaceuticals by 229.4% in the 1st quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock valued at $11,576,000 after purchasing an additional 104,828 shares during the period. Janus Henderson Group PLC lifted its stake in shares of ANI Pharmaceuticals by 1,308.1% in the 1st quarter. Janus Henderson Group PLC now owns 109,552 shares of the specialty pharmaceutical company’s stock valued at $8,425,000 after purchasing an additional 101,772 shares during the period. California State Teachers Retirement System boosted its position in shares of ANI Pharmaceuticals by 57.3% during the 1st quarter. California State Teachers Retirement System now owns 24,557 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after purchasing an additional 8,946 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 143 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $78.37 on Friday. The firm has a market cap of $1.78 billion, a PE ratio of 19.84 and a beta of 0.43. The firm’s fifty day moving average is $81.24 and its 200-day moving average is $79.48. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals has a 52 week low of $62.60 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.